Extending the time limit for clot-busting stroke drugs means more recover

Embargoed until: Publicly released:

Doubling the length of time that clot-busting drugs can be used after a stroke results in more patients making a full recovery, according to Australian-led research. Current stroke guidelines limit the time to use clot-busting drugs to within 4.5 hours after the onset of stroke, but this new study found extending this up to nine hours after a stroke in suitable cases resulted in a higher percentage of patients with no or minimal deficits, compared with placebo. There were more cases of bleeding in the brain with the treatment than placebo.

Journal/conference: New England Journal of Medicine

Link to research (DOI): 10.1056/NEJMoa1813046

Organisation/s: Florey Institute of Neuroscience and Mental Health, The University of Melbourne, The Royal Melbourne Hospital, Monash University, La Trobe University, University of Newcastle, University of Sydney, Royal Adelaide Hospital, University of Queensland, Griffith University, University of Auckland

Funder: Supported by the Australian National Health and Medical Research Council and the Commonwealth Scientific and Industrial Research Organization Flagship Program. The EXTEND trial sites in Taiwan were supported in part by a Ministry of Health and Welfare grant (MOHW108-TDU-B-212-133004) and the Ministry of Science and Technology Taiwan Clinical Trial Consortium for Stroke (MOST107-2321-B-039-004). Full disclosures in paper

Media Release

From: The Royal Melbourne Hospital

Australian study will change the way stroke is treated around the world

A team of Melbourne researchers have found the time to treat ischemic stroke patients can be doubled. One in five people suffer stroke in their sleep and this will be life changing for them.

The EXTEND randomised clinical trial found  the initial window of 4.5 hours from symptom onset could now be pushed to 9 hours given solid evidence of ‘brain to save’ on advanced brain imaging.

EXTEND, led by The Royal Melbourne Hospital, the University of Melbourne and Monash Health, compared the effectiveness of altephase, a thrombolytic drug used to treat ischemic stroke, versus placebo, for reducing disability after stroke.

The research found in most cases if the patient was administered the alteplase between 4.5 – 9 hours after stroke onset it resulted in a high percentage of patients with no or minor neurologic defects than the use of placebo.

RMH neurologist, Director of the Melbourne Brain Centre at RMH and study co-principal investigator Professor Stephen Davis said the study, published in the New England Journal of Medicine found the drug alteplase was life changing in treatment of ischemic stroke.

“Our study used imaging of brain blood flow to select patients and showed that alteplase increased the number of patients who were able to return to all their usual activities by 44% compared to placebo , an excellent outcome for our patients,” Professor Davis said.

The international trial involved 225 participants from a large multi-centre collaboration across 25 hospitals in Australia, New Zealand, Finland and Taiwan, who either received alteplase or placebo.

Professor Geoffrey Donnan, study co-principal investigator, said the study results were likely to change stroke treatment guidelines and clinical practice.

“This research means that patients who were previously untreatable because they woke up with stroke symptoms or were unavoidably delayed in reaching hospital can now benefit,” Professor Donnan said.

While this breakthrough will lead to sweeping changes in stroke treatment it’s still critical people seek help as soon as possible as Professor Davis warns that every minute counts when it comes to stroke patients.

“It’s still critical that stroke patients are treated as fast as possible and the proportion of patients who have the favourable brain imaging that allows us to treat them drops rapidly with passing time,” Professor Davis said.

Medical co-ordinator for the EXTEND trial Associate Professor Henry Ma from Monash Health said the research means patients who have a stroke in their sleep will greatly benefit.

“These results shift the stroke paradigm from using a clock to determine eligibility for clot-dissolving treatment to using brain imaging to identify whether there is brain tissue that can be saved in the individual patient, A/Prof Ma said.

“This is terrific for patients and will reduce the burden of stroke-related disability in Australia and worldwide.”

MEDIA EVENT:

WHEN: Friday 10 April, at 10am.

WHERE: The Royal Melbourne Hospital, Grattan Street, Parkville. Please meet at main reception.

INTERVIEW:

  • Prof Stephen Davis Royal Melbourne Hospital Neurologistand co-principal investigator
  • A/Prof Henry Ma, Monash Health, trial medical co-ordinator
  • Patricia Thomas, suffered a stroke five years ago and was part of this study, she was able to walk out of the hospital with no disability and was back playing tennis within a month of her stroke, herself and her husband Bruce can talk about those experiences

Media contact: Rose Houghton, Communications 0431 481 588

Attachments:

Note: Not all attachments are visible to the general public

  • Massachusetts Medical Society
    Web page
    Please link to the article in online versions of your report (the URL will go live after the embargo ends).

News for:

Australia
New Zealand
NSW
VIC
QLD
SA

Media contact details for this story are only visible to registered journalists.